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Objective: To establish guidelines based on cientiﬁc evidences for the management of cry-
opyrin associated periodic syndromes.
Description of the evidence collection method: The Guideline was prepared from 4 clinical ques-
tions that were structured through PICO (Patient, Intervention or indicator, Comparison
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and Outcome), to search in key primary scientiﬁc information databases. After deﬁning the
potential studies to support the recommendations, these were graduated considering their
strength of evidence and grade of recommendation.
Results: 1215 articles were retrieved and evaluated by title and abstract; from these, 42
articles were selected to support the recommendations.
Recommendations: 1. The diagnosis of CAPS is based on clinical history and clinical manifesta-
tions, and later conﬁrmed by genetic study. CAPS may manifest itself in three phenotypes:
FCAS  (mild form), MWS  (intermediate form) and CINCA (severe form). Neurological, oph-
thalmic, otorhinolaryngological and radiological assessments may be highly valuable in
distinguishing between syndromes; 2. The genetic diagnosis with NLRP3 gene analysis must
be conducted in suspected cases of CAPS, i.e.,  individuals presenting before 20 years of age,
recurrent episodes of inﬂammation expressed by a mild fever and urticaria; 3. Laboratory
abnormalities include leukocytosis and elevated serum levels of inﬂammatory proteins; and
4.  Targeted therapies directed against interleukin-1 lead to rapid remission of symptoms in
most patients. However, there are important limitations on the long-term safety. None of
the three anti-IL-1 inhibitors prevents progression of bone lesions.
©  2015 Elsevier Editora Ltda. All rights reserved.
Diretrizes  de  conduta  e  tratamento  de  síndromes  febris  periódicas
associadas  à  criopirina  (criopirinopatias  –  CAPS)
Palavras-chave:
Síndrome autoinﬂamatória
familiar associada ao frio
Síndrome de Muckle-Wells




r  e  s  u  m  o
Objetivo: Estabelecer diretrizes baseadas em evidências cientíﬁcas para manejo das Sín-
dromes periódicas associadas à criopirina (Criopirinopatias – CAPS).
Descric¸ão do método de coleta de evidência: A Diretriz foi elaborada a partir de 4 questões
clínicas que foram estruturadas por meio do P.I.C.O. (Paciente, Intervenc¸ão ou Indicador,
Comparac¸ão  e Outcome), com busca nas principais bases primárias de informac¸ão cientíﬁca.
Após deﬁnir os estudos potenciais para sustento das recomendac¸ões, estes foram graduados
pela  forc¸a da evidência e grau de recomendac¸ão.
Resultado: Foram recuperados, e avaliados pelo título e resumo, 1215 artigos, tendo sido
selecionados 42 trabalhos, para sustentar as recomendac¸ões.
Recomendac¸ões: 1. O diagnóstico de CAPS é baseado na anamnese e manifestac¸ões clíni-
cas, sendo posteriormente conﬁrmado por estudo genético. Pode se manifestar sob três
fenótipos: FCAS (forma leve), MWS (forma intermediária) e CINCA (forma grave). Avaliac¸ões
neurológica, oftalmológica, otorrinolaringológica e radiológica podem ser de grande valia na
distinc¸ão  entre as síndromes; 2. O diagnóstico genético com análise do gene NLRP3 deve ser
conduzido nos casos suspeitos de CAPS, isto é, indivíduos que apresentam, antes dos 20 anos
de  idade, episódios recorrentes de inﬂamac¸ão expressa por urticária e febre moderada;
3.  As alterac¸ões laboratoriais incluem leucocitose e elevac¸ão nos níveis séricos de proteínas
inﬂamatórias; 4. Terapias alvo dirigidas contra a interleucina 1 levam a rápida remissão dos
sintomas na maioria dos pacientes. Contudo, existem limitac¸ões importantes em relac¸ão
à  seguranc¸a em longo prazo. Nenhuma das três medicac¸ões anti-IL1 evita progressão das
lesões ósseas.








wescription  of  the  evidence  collection  method
his Guideline was prepared from 4 relevant clinical questions
elated to the management of cryopyrin-associated periodical
yndromes (cryopyrinopathies). The questions were struc-
ured by the use of PICO (Patient, Intervention or indicator,
omparison and Outcome), allowing the generation of strate-
ies for searching evidence (described after each question,
ith the number of recovered articles), in the main primarydatabases of scientiﬁc information (Medline/Pubmed, Embase,
Lilacs/Scielo, Cochrane Library). The recovered evidence has
been selected from a critical evaluation using discrimina-
tory instruments (scores): JADAD and GRADE for Randomized
Clinical Trials, and New Castle Ottawa scale for obser-
vational studies. After deﬁning the potential studies to
support the recommendations, these articles were rated
based on the strength of evidence and grade of recommen-
dation, according to the classiﬁcation of Oxford (available
 t o l .46  r e v b r a s r e u m a
at www.cebm.net), including available evidence of greatest
strength.
Summary  of  grades  of  recommendation
and  strength  of  evidence
A. Experimental or observational studies of higher consis-
tency
B. Experimental or observational studies of lower consistency
C. Case reports (non-controlled studies).
D. Expert opinion without explicit critical appraisal, or based
on physiology or bench research.
Objective
To establish guidelines based on scientiﬁc evidence for the
management of cryopyrin-associated periodical syndromes
(cryopyrinopathies).
Introduction
Cryopyrin-associated periodic syndromes (CAPS) comprise
a speciﬁc, rare group of monogenic autoinﬂammatory dis-
eases which are included in the group of hereditary periodic
fever syndromes caused by a defect in the regulation of
inﬂammatory cytokines, particularly interleukin-1  (IL-1).
These diseases include the familial cold-associated autoin-
ﬂammatory syndrome (FCAS); Muckle–Wells syndrome (MWS)
and chronic infantile neurological, cutaneous, and articular
(CINCA) syndrome, also known as neonatal-onset multisys-
tem inﬂammatory disease (NOMID).
1. When should we  suspect that an individual is a
carrier of cryopyrin-associated periodical syndromes (cryopy-
rinopathies)?
Strategy
(Cryopyrin-Associated Periodic Syndromes OR Urticarias,
Familial Cold OR Familial Cold Autoinﬂammatory Syndrome
1 OR Muckle–Wells Syndrome OR Chronic Neurologic Cuta-
neous and Articular Syndrome OR NOMID OR Prieur–Griscelli
Syndromes OR Cryopyrinopathy OR UDA Syndromes OR
Chronic Infantile Neurological, Cutaneous, and Articular Syn-
drome OR Neonatal Onset Multisystem Inﬂammatory Disease)
AND Signs and Symptoms. n = 543.
The cryopyrin-associated periodic syndromes (CAPS)
are autoinﬂammatory diseases characterized by recurrent
episodes of systemic inﬂammation, involving multiple tis-
sues, including joints, skin, central nervous system (CNS),
eyes and ears. Contrary to what happens with autoimmune
diseases, CAPS are not associated with immune response
through autoantibodies or antigen-speciﬁc T cells, but with
the dysfunction of the innate immune system, which is
not speciﬁc, not requiring initial sensitization by antigen.1
(D)Familial cold-associated autoinﬂammatory syndrome,
Muckle–Wells syndrome and chronic infantile neurological,
cutaneous and articular syndrome were originally described 2 0 1 6;5 6(1):44–51
as distinct clinical entities, despite the overlapping of symp-
toms and signs.2 (D) Patients often are seen with recurrent
episodes of fever and pseudourticariform rash, as well as with
inﬂammation of tissues such as joints, brain, ears and eyes.
Indeed, these three syndromes exist in a progression of sever-
ity, with familial cold-associated autoinﬂammatory syndrome
being the least severe condition and CINCA the most severe of
them; MWS  has an intermediate phenotype of severity. Skin
rash, a signal present in all three diseases, is usually the ﬁrst
manifestation to develop after birth or in early childhood. This
condition has a migratory, maculopapular, urticariform rash,
and usually is associated with pruritus.2,3 (D)
Familial cold-associated autoinﬂammatory syndrome
(FCAS), or cold-induced urticaria, is the mildest form of
CAPS and has an autosomal dominant trait. FCAS is char-
acterized by recurrent and self-limited episodes of mild
fever, skin rash and arthralgia, precipitated by exposure to
environmental changes characterized by low temperatures
(e.g., wind exposure, refrigerator door opening). FCAS differs
from cold-induced hives, where contact with cold surfaces
is the triggering factor. Other related symptoms include
conjunctivitis, myalgia, sweating, somnolence, headache,
and nausea.4 (C) Symptoms usually begin a few hours after
exposure to low temperatures, usually with a short duration
of episodes.5 (C) Although late cases of renal amyloidosis have
been reported in family members affected by FCAS, deafness
and amyloidosis are not usually observed in this syndrome,
as opposed to what occurs in MWS  and CINCA patients.6
(C)
Muckle–Wells Syndrome (MWS), is characterized by
episodes of urticaria and deafness, and renal amyloidosis.7
(C) Recurrent episodes of fever and skin rash associated with
joint and ocular manifestations were described, although not
always with fever.8 (C) The course of the disease varies, from
recurrent attacks to permanent symptoms.9 (C) As in FCAS,
conjunctivitis is often present. Neurological impairment is
often not described, although in some cases headache and
papilledema have been reported. Amyloidosis is the most
severe complication, developing into adulthood in approxi-
mately 30% of the cases.8 (C) Sensorineural hearing loss is
observed in 70% of cases.10 (D)
Chronic infantile neurological, cutaneous and articular
(CINCA) syndrome, also known as neonatal-onset multisys-
tem inﬂammatory disease (NOMID), is associated with the
most severe phenotype of this spectrum of diseases.11 (C) The
ﬁrst symptoms of CINCA occur already in the ﬁrst weeks of life
or in early childhood.12 (C) Fever can be an intermittent and
mild ﬁnding; in some cases this sign is even absent. Skin rash
is variable among individuals, depending from disease activ-
ity. Involvement of bones and joints also varies in severity: in
approximately two thirds of these patients, joint manifesta-
tions, mainly in large joints, are limited to transient arthralgia
and edema. However, in one third of patients a crippling
arthropathy can be seen.12 (C) Patients with CINCA/NOMID can
also exhibit an excessive growth of epimetaphysary cartilage,
particularly of long bones, which eventually causes deforma-
tions leading to a discrepancy in the length of limbs, joint
contractures and degenerative arthropathy.13,14 (C) CNS abnor-
malities are present in almost all patients and are caused
by chronic aseptic meningitis through leukocyte inﬁltration.12
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C) Headache, seizures, mental retardation, spasticity of the
ower limbs and papilledema are often observed as a conse-
uence of an increased intracranial pressure. Eye involvement
ith identiﬁcation of uveitis occurs in approximately 50% of
atients, with posterior uveitis in around 20%. Optic atrophy
ay also develop, and ocular manifestations can progress
o blindness.15,16 (C) Sensorineural hearing loss can also be
oted.
ecommendation
he diagnosis of CAPS is based on clinical history and clinical
anifestations, being later conﬁrmed by genetic studies. CAPS
ay manifest itself in three phenotypes, with no ﬁxed demar-
ation among them: FCAS (mild form), MWS  (intermediate
orm) and CINCA (severe form).17 (C) The distinction between
hese cryopyrinopathies may be a difﬁcult task, since they
ave symptoms in common. Neurological, ophthalmic, otorhi-
olaryngological and radiological assessments can be critical
n distinguishing among the syndromes.
2. How the genetic diagnosis of cryopyrin-associated peri-
dical syndrome is established?
trategy
Cryopyrin-Associated Periodic Syndromes OR Urticarias,
amilial Cold OR Familial Cold Autoinﬂammatory Syndrome
 OR Muckle–Wells Syndrome OR Chronic Neurologic Cuta-
eous and Articular Syndrome OR IOMID OR Prieur–Griscelli
yndromes OR Cryopyrinopathy OR UDA Syndromes OR
hronic Infantile Neurological, Cutaneous, and Articular Syn-
rome OR Neonatal Onset Multisystem Inﬂammatory Disease)
ND (Medical Genetics[ﬁlter]). n = 270.
Periodic syndromes associated with cryopyrin are caused
y mutations (with an autosomal dominant pattern, or de
ovo mutations) in CIAS1 gene – cold-induced autoinﬂamma-
ory syndrome 1, also known as NLRP3 or NALP3 (NACHT,
ucleotide binding oligomerization domain, leucine rich-
epeat family, pyrin domains containing protein 3), located
n chromosome 1q44. The mechanism by which mutations
n the gene CIAS1 cause inﬂammatory diseases is not fully
nderstood, however in vitro studies suggest that these muta-
ions present a function gain effect, probably through loss
f regulatory mechanisms associated with activation.18 (D)
o far, the online database known as Infevers, dedicated to
utoinﬂammatory hereditary diseases, describes more  than
70 mutations related to CAPS.19 (D)
This gene encodes the protein cryopyrin, which belongs
o a family of proteins called nucleotide binding domain
nd leucine-rich repeats (NLR), predominantly expressed in
eripheral blood leukocytes.10,20 (D) Cryopyrin is related to
he regulation of caspase-1, and changes in its concentration
ause overexpression of IL-1, and this increased production
riggers recurrent episodes of systemic inﬂammation. Cryopy-
in is also involved in the regulation of the apoptosis pathway
nd in the activation of nuclear factor kappa B, despite
onﬂicting evidence on the activation of this factor.21,22 (D) Dif-
erent mutations in CIAS1 gene have been linked to CAPS, and
ome of these mutations are exclusively related to one of these 0 1 6;5  6(1):44–51 47
syndromes (FCAS, MWS  and/or CINCA/NOMID).23 (D) It is fur-
ther recognized that in about 50% of patients with a diagnosis
of CINCA/NOMID and in around 25–33% of patients with MWS,
NLRP3 mutations are not identiﬁed.24 (C)
Because this is a genetic disease that follows an autoso-
mal  dominant pattern, individuals with CAPS usually have
one of their parents affected by the disease, with a 50%
probability of having their offspring affected.25 (D) Patients
with CINCA/NOMID are usually affected by mutations de novo,
with no family history of CAPS.
Recommendation
The genetic diagnosis with an analysis of NLRP3 gene must
be obtained in suspected cases of CAPS, i.e.,  individuals pre-
senting, recurrent episodes of inﬂammation expressed by mild
fever and urticaria before the age of 20. It should be left
clear, however, that in fact a signiﬁcant number of individ-
uals clinically diagnosed as carriers of cryopyrinopathy have
no mutations associated with the disease.
3. Besides genetic studies, what tests should be required
for the evaluation of patients with cryopyrin-associated peri-
odical syndrome?
Strategy
(Cryopyrin-Associated Periodic Syndromes OR Urticarias,
Familial Cold OR Familial Cold Autoinﬂammatory Syndrome
1 OR Muckle–Wells Syndrome OR Chronic Neurologic Cuta-
neous and Articular Syndrome OR IOMID OR Prieur–Griscelli
Syndromes OR Cryopyrinopathy OR UDA Syndromes OR
Chronic Infantile Neurological, Cutaneous, and Articular Syn-
drome OR Neonatal Onset Multisystem Inﬂammatory Disease)
AND (Diagnosis/Broad[ﬁlter]). n = 203.
Usually, acute-phase proteins, such as C reactive protein
(CRP) and serum amyloid A protein (SAA), exhibit increased
serum levels, despite the absence of cutaneous signs; thus,
these indicators should be monitored.26,27 (D) Neutrophilia
may also occur. Proteinuria and renal function tests should
be performed, since progression to nephrotic syndrome
and renal failure reﬂects a late complication of systemic
amyloidosis.
Cerebrospinal ﬂuid examination can be conducted in
suspected cases of CINCA/NOMID and MWS.  High polymor-
phonuclear cell counts, high concentration of protein and an
increase in intracranial pressure can be found.27,28 (D,C) Imag-
ing studies such as CT scan or brain MRI  should be obtained,
conﬁrming the diagnosis. These studies can identify ventricu-
lar dilatation with a prominent sulcus and central atrophy.29
(C) Plain radiographs can identify bone and joint involvement
through the demonstration of metaphyseal osteopathy and
impairment of growth plates.30 (C) Audiometry is an important
test for the establishment of an early diagnosis and mon-
itoring of sensorineural hearing loss; also important is an
ophthalmic evaluation.Recommendation
Laboratory changes are the same observed in other autoin-
ﬂammatory diseases, including leukocytosis and higher
 t o l .48  r e v b r a s r e u m a
serum levels of inﬂammatory proteins; these should be moni-
tored. Imaging studies may be critical in distinguishing among
syndromes, as well as for the ophthalmologist and otolaryn-
gologist evaluation.
The scarcity of periodic syndromes associated with cry-
opyrin and the presence of overlapping symptoms with other
conditions often result in a delay in the establishment of
a diagnosis. Because of the different phenotypes related to
CAPS, a review of clinical symptoms is in order, as well as a
combination of diagnostic procedures.
4. What is the role of biological agents in the management
of cryopyrin-associated periodical syndrome?
Strategy
(Cryopyrin-Associated Periodic Syndromes OR Urticarias,
Familial Cold OR Familial Cold Autoinﬂammatory Syndrome
1 OR Muckle–Wells Syndrome OR Chronic Neurologic Cuta-
neous and Articular Syndrome OR IOMID OR Prieur–Griscelli
Syndromes OR Cryopyrinopathy OR UDA Syndromes OR
Chronic Infantile Neurological, Cutaneous, and Articular
Syndrome OR Neonatal Onset Multisystem Inﬂammatory Dis-
ease) AND (Interleukin 1 Receptor Antagonist Protein OR
Anakinra OR Urine-Derived IL1 Inhibitor OR IL1 Inhibitor,
Urine-Derived OR Urine Derived IL1 Inhibitor OR IL1 Febrile
Inhibitor OR Febrile Inhibitor, IL1 OR inﬂiximab OR etanercept
OR adalimumab OR golimumab OR certolizumab OR Tumor
Necrosis Factor alpha OR Cachectin-Tumor Necrosis Factor OR
Cachectin Tumor Necrosis Factor OR TNFalpha OR TNF-alpha
OR Tumor Necrosis Factor OR Tumor Necrosis Factor Ligand
Superfamily Member 2). n = 199.
IL-1  receptor  antagonist
The proposed use of drugs targeting the blockage of the
inﬂammatory cytokine activation pathway is based on the
identiﬁcation of defects in the regulation of these cytokines,
where signiﬁcantly elevated serum levels are observed. Three
different types of IL-1 receptor antagonists are available:
human recombinant non-glycosylated analog of IL-1 recep-
tor antagonist (rhIL-1Ra) (anakinra); fusion protein comprising
type I receptor of IL-1; and accessory protein of IL-1 recep-
tor and the Fc portion of human IgG1 (rilonacept) and human
monoclonal antibody against IL-1 (canakinumab).31 (D)
1. Anakinra (human recombinant non-glycosylated analog of IL-1
receptor antagonist)
The mechanism of action of anakinra is a competitive
inhibition of binding of IL-1 and IL-1 to their receptors.32
(D) The ﬁrst study on the use of anakinra in patients with
CAPS was a case report of two patients diagnosed with MWS
presenting, as clinical features, fever, skin rash, conjunctivi-
tis and increased serum levels of serum amyloid A.33 (C) In
this study, treatment with anakinra (100 mg/day) provided
improvement of inﬂammatory symptoms hours after admin-
istration of the drug, and both patients showed a reduction
in serum levels of amyloid A. This response was found to be
maintained throughout a six-month follow-up period in both
patients, with a substantial reduction in inﬂammatory protein
levels.33 (C) 2 0 1 6;5 6(1):44–51
In a prospective study, an analysis was conducted on
18 patients (age range, 4–32 years) diagnosed with CINCA,
where all of them should have at least two of the follow-
ing symptoms: skin rash, central nervous system impairment
(expressed by hearing loss and papilledema), and osteopathy
identiﬁed by patella or epiphysis overgrowth. In this study,
it was found that the treatment with anakinra (1.0 mg/kg)
was  associated with skin rash and conjunctivitis resolution
three days after administration of the drug.34 (C) One month
after the initiation of treatment, a decrease in inﬂammatory
proteins (amyloid A and C-reactive protein), as well as in
erythrocyte sedimentation rate, was noted; and these reduced
levels were maintained through the six-month evaluation.34
(C) Overall, eight patients had remission of inﬂammatory
symptoms in the 3rd month of follow-up, while the remain-
der (n = 10) showed remission at 6 months. With regard to
adverse events, the most commonly reported ones were reac-
tions at the site of application, and upper respiratory tract
infection.34 (C)
A retrospective study analyzing patients with CAPS found
that 15 patients treated with anakinra showed complete
remission in disease activity within 12 h after administra-
tion of the drug.35 (C) In this study it was also observed that
serum levels of C-reactive protein and of amyloid A returned
to normal one week after the initiation of treatment.35 (C)
Another study on quality of life of children diagnosed with
CAPS showed that the use of anakinra for a mean period
of 37.5 months produced signiﬁcant improvement in overall
quality of life, analyzed by CHQ (Child Health Questionnaire)-
PF50.36 (C)
2. Rilonacept (fusion protein comprising type I IL-1 receptor, IL-1
receptor accessory protein, and the Fc portion of human IgG1)
Rilonacept is a dimeric fusion protein consisting of the
extracellular domain of interleukin-1 receptor and of human
IgG1 Fc domain that binds and neutralizes IL-1. This was
the ﬁrst drug approved by the FDA (Food and Drug Admin-
istration) for the treatment of CAPS, speciﬁcally focused on
FCAS and MWS.  In 2008, an analysis of results of 47 patients
with FCAS and MWS  enrolled in two consecutive phase III
studies was conducted. The ﬁrst of these, a double-blind,
randomized study with a six-week follow-up, compared the
administration of weekly subcutaneous injections of rilona-
cept 160 mg/week versus placebo. The second study consisted
of two parts: Part A – nine weeks of an open-phase treatment
with rilonacept; and Part B – Nine-week of a double-blind, ran-
domized, placebo-controlled study of drug discontinuation. In
this study, it was shown that rilonacept administration was
associated with improvement in disease activity within a few
days of the onset of therapy (an improvement of 84% in the
symptom score in the treated group versus 13% in placebo
group).37 (A) A decrease in serum levels of C-reactive pro-
tein and serum amyloid A versus baseline values was also
found.37 (A) An extension of this analysis with a 96-week
follow-up period showed continued improvement in signs and
symptoms, as well as maintenance of low serum levels of
inﬂammatory proteins.38 (B) With regard to adverse events,
reaction at the site of drug application, upper respiratory tract
infection, headache, and diarrhea were the most frequently
reported.37,38 (A,B)
3. Canakinumab (monoclonal antibody against human IL-1ˇ)
























































rr e v b r a s r e u m a t
Canakinumab, approved in 2009 by the FDA, is directed to
he treatment of children over four years and adults with a
iagnosis of FCAS and MWS.  This is a human monoclonal anti-
ody against IL-1 with high afﬁnity to binding human IL-1,
locking its interaction with receptors and therefore neutral-
zing its activity.
The ﬁrst randomized controlled trial examining the use of
anakinumab in patients with CAPS was completed in 2008
nd consisted of three parts. In phase 1, 35 patients received
anakinumab 150 mg.  Those with complete response to treat-
ent entered part 2 of the study and were randomly assigned
o treatment with canakinumab every eight weeks for up to
4 weeks versus non-treatment. After the completion of phase
 or in face of the occurrence of relapse, phase 3 was initi-
ted, in which the participants received at least two more
oses of canakinumab.39 (A) In Phase 1, this study showed
open-label) complete response with respect to improvement
f disease symptoms in 97% of patients (34/35). During phase
 (double-blind), all 15 patients randomized to treatment with
anakinumab remained in remission of the disease, in con-
rast to 81% (15/16) of patients randomized to placebo, who
howed active disease (including high serum levels of C-
eactive protein and serum amyloid A). At the end of this
hase, 52% of patients treated with canakinumab reported
emission of symptoms, compared to zero patients in placebo
roup. This study also identiﬁed that 75% of untreated patients
emained with symptoms of mild to moderate intensity, com-
ared to zero patients treated with canakinumab.39 (A) In this
tudy, the use of canakinumab was well tolerated, with only
wo patients reporting serious adverse events, including a
ertigo episode followed by closed-angle glaucoma related to
omplications of CAPS, and lower urinary tract infection and
epsis. The most commonly reported adverse events among
hose receiving the drug were pharyngitis, rhinitis, nausea,
iarrhea and vertigo. Most patients reported no reactions at
he injection site.39 (A)
In agreement with the ﬁndings described above, one mul-
icenter phase III study (open-label) also associated the use
f canakinumab to improvement of symptoms and suppres-
ion of systemic inﬂammation, with normalization of serum
-reactive protein and amyloid A.40 (B) This study aimed to
xamine the effects, in the long run, of the use of canakinumab
150 mg  or 2.0 mg/kg every eight weeks, over more  than two
ears) in patients with previously untreated CAPS, or who
ad already been treated in previous studies.40 (B) A com-
lete response was achieved (according to evaluation scores
f disease activity) by 78% (85/109) of those treatment-naive
atients. The adverse events noted were considered to be of
ild to moderate intensity; most patients (92%) reported hav-
ng suffered no reaction at the injection site.40 (B)
ecommendation
argeted therapies directed against cytokines (interleukin-1 in
his case) are associated with a rapid remission of symptoms
n most patients diagnosed with CAPS. The use of rilonacept
or patients with FCAS and MWS  demonstrated improvement
n disease activity in a follow-up period of 6–96 weeks, with
educed serum levels of inﬂammatory proteins (C-reactive
rotein and amyloid A). The use of canakinumab also pro- 0 1 6;5  6(1):44–51 49
moted reduction of clinical manifestations. However, there are
signiﬁcant limitations on the use of these drugs, especially in
relation to short follow-ups, small number of patients eval-
uated, intrinsic bias when evaluating rare diseases, and in
comparing the efﬁcacy of treatment with placebo, parameters
that prevent a more  robust assessment of the effectiveness
of these drugs, as well as in relation to their safety, taking
into account their potential long-term risks. In the literature,
two  studies demonstrating ongoing efﬁcacy using anakinra
were found.41,42 It is not yet clear whether rilonacept or
canakinumab offer a therapeutic option for treatment of asep-
tic meningitis, ocular impairment or hearing loss. None of the
three anti-IL-1 medications prevent the progression of bone
lesions.41 Worldwide, the high cost of these biologicals, which
are drugs of chronic use in all patients, is still the main limita-
tion to its use in clinical practice of pediatric rheumatologists.
Usually an increase of the dose, or even a change of immuno-
biological agent during the follow-up, is needed. Importantly,
we do not count on direct comparisons of the three different
types of IL-1 receptor antagonists currently available. Conse-
quently, it becomes impossible to suggest preferentially one
or other of these drugs based on evidence.
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